Selpercatinib as the Guardian of the Central Nervous System for Patients With RET Fusion-Positive NSCLC?

J Thorac Oncol. 2023 May;18(5):561-563. doi: 10.1016/j.jtho.2023.02.005.

Authors

Sally C M Lau¹, Sai-Hong Ignatius Ou²

Affiliations

¹ Department of Medical Oncology, NYU Langone Perlmutter Cancer Center, NYU Grossman School of Medicine; New York, New York.
² Division of Hematology-Oncology, Department of Medicine, University of California Irvine School of Medicine, Orange, California; Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, California. Electronic address: siou@hs.uci.edu.

PMID: 37087118
DOI: 10.1016/j.jtho.2023.02.005

No abstract available

Publication types

Editorial
Comment

MeSH terms

Central Nervous System / drug effects
Humans
Lung Neoplasms* / drug therapy
Lung Neoplasms* / genetics
Proto-Oncogene Proteins c-ret / genetics
Pyrazoles
Pyridines

Substances

Proto-Oncogene Proteins c-ret
Pyrazoles
Pyridines
RET protein, human
selpercatinib